The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients

J Acquir Immune Defic Syndr. 2011 Apr;56(4):340-3. doi: 10.1097/QAI.0b013e31820bf84c.

Abstract

We sought to determine the effects of interleukin-2 administered in combination with antiretroviral therapy (ART) on CD4+ T cells in the gut. Lymphocytes from whole blood, colon, and terminal ileum of HIV-infected adults treated with interleukin-2 and ART or ART alone were examined. There were no differences between groups in the proportion of CD4+ T cells or in expression of CD25 or Ki67 by CD4+ T cells in the gut. Although IL-2 administration leads to expansion of peripheral blood CD4+ T cells, there is no alteration in the proportion or activation of CD4+ T cells in the gut mucosa.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods*
  • CD2 Antigens / analysis
  • CD4-Positive T-Lymphocytes / chemistry
  • CD4-Positive T-Lymphocytes / immunology*
  • Gastrointestinal Tract / immunology*
  • HIV Infections / drug therapy*
  • Humans
  • Interleukin-2 / therapeutic use*
  • Ki-67 Antigen / analysis
  • Middle Aged
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • CD2 Antigens
  • Interleukin-2
  • Ki-67 Antigen